Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Vection Technologies

    MCap

    AUD11m

    Last close

    AUD0.01

    ▲ 0.00 (12.50%)

    bet-at-home

    MCap

    EUR25m

    Last close

    EUR3.50

    ▲ 0.31 (9.72%)

    Recce Pharmaceuticals

    MCap

    AUD127m

    Last close

    AUD0.55

    ▲ 0.04 (6.86%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

IRLAB Therapeutics (OMX: IRLAB-A)

Last close As at 09/09/2024

SEK14.25

▲ −0.15 (−1.04%)

Market capitalisation

SEK738m

Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD).

PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.

Latest Insights

View More

Healthcare | Flash note

IRLAB Therapeutics — New mesdopetam patent strengthens IP portfolio

Healthcare | edison tv

IRLAB Therapeutics – executive interview

Healthcare | Update

IRLAB Therapeutics — Anticipation builds as inflection points approach

Healthcare | Flash note

IRLAB Therapeutics — Pirepemat passes Phase IIb DSMB safety hurdle
IRLAB Therapeutics_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Viktor Siewertz

    CFO

Balance Sheet

Forecast net cash (SEKm)

74.2

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (11.8) 1.1 83.6
Relative (14.8) 4.6 55.6
52 week high/low SEK19.6/SEK5.9

Financials

IRLAB Therapeutics has been granted a new patent in Europe for its lead asset, Phase-III ready mesdopetam, which potentially extends its market exclusivity beyond the previous 2037 expiry. The updated patent relates to a new salt of the drug (which has been used during the ongoing clinical development) and the process for its preparation, extending protection to 2040. Mesdopetam is IRLAB’s most advanced asset, targeting levodopa-induced dyskinesias in Parkinson’s disease (PD-LIDs), a debilitating condition inflicting over 30% of the PD patient population. Following IRLAB’s successful end-of-Phase II (EoP2) meeting with the FDA, we believe that Phase III trials could start as early as Q424 or Q125, depending on partnership discussions. We view this as the most significant upcoming catalyst for the company.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2022A 61.3 (108.3) (113.1) (218.0) N/A N/A
2023A 5.7 (176.5) (177.8) (343.0) N/A N/A
2024E 75.6 (147.0) (154.8) (298.0) N/A N/A
2025E 27.5 (172.9) (180.9) (349.0) N/A N/A

Research

edison tv

Healthcare

IRLAB Therapeutics – executive interview

Update

Healthcare

IRLAB Therapeutics — Anticipation builds as inflection points approach

Healthcare

Flash note

IRLAB Therapeutics — New mesdopetam patent strengthens IP portfolio
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free